Legend Biotech Director Mao Li Receives RSU Award of 20,986 Shares

What Happened

• Mao Li, a director of Legend Biotech Corp (NASDAQ: LEGN), was granted 20,986 restricted share units (RSUs) on September 24, 2026. The Form 4 reports an acquisition at $0.00 per share (award/grant), with a reported cash value of $0 at grant (this reflects no cash paid at grant; fair value for accounting may be disclosed elsewhere).
• This is an award (transaction code A), not an open-market purchase or sale — typically a compensatory/grant event rather than a trading signal.

Key Details

• Transaction date: 2026-09-24; Form 4 filed: 2026-09-28 (filed within the usual two business-day window).
• Award: 20,986 RSUs; acquisition price reported: $0.00; reported cash outlay: $0.
• Shares owned after transaction: not disclosed in this Form 4 filing.
• Footnote highlights:
  • F1: Ordinary shares may be represented by ADSs (each ADS = 2 ordinary shares).
  • F2: These are RSUs. Vesting schedule: 1/3 vests on December 20, 2027; remaining RSUs vest in 12 equal quarterly installments beginning March 20, 2028, subject to continued service.
• Transaction code: A = Award/Grant (not a purchase or sale).

Context

• RSU grants are common director/employee compensation and do not necessarily indicate immediate bullish or bearish trading intentions. These RSUs will convert to ordinary shares only as they vest.
• No indication of a cashless exercise, sale, or tax-withholding disposition in this filing. If and when shares vest or are sold, subsequent Form 4s will report those transactions.